Diagnosis and Management of Major or Persistent Depression in the HIV-Infected Patient

Overview

CME Credit Available: 1.50 AMA PRA Category 1 Credits
Level: Advanced
Release Date: February 16, 2015
Date of Last Review/Update: September 23, 2017
Expiration Date: September 23, 2018

 

This Cases on the Web activity introduces a case and presents clinical decision points, each focusing on an HIV-infected man with major depression and other complicating mental health problems.

At each decision point, learners should select the option that they think is most sound and then read the presenters’ explanation of that option. Selecting the correct option links the learner to an extended discussion of the related medical findings, research-based evidence, and case management considerations.

To advance from one clinical decision point to the next, learners should click on the NEXT arrow located at the bottom of the page that discusses the best clinical option.

After reviewing the cases, learners may access the activity posttest and the course evaluation, both of which must be completed and submitted to claim continuing medical education (CME) credit or a certificate of participation or continuing education units (CEUs) or pharmacy credits. Please see the posttest form and course evaluation form for further instructions.

 

Learning Objectives

On completion of this activity, the learner will be able to:

  • Describe the approach to the diagnosis of depression among people with HIV infection, including the differential diagnosis
  • Determine the management of depression in people with HIV infection, including interactions between antidepressants and antiretroviral medications
  • Develop strategies for managing some of the comorbidities that commonly complicate the treatment of depression in people with HIV infection

 

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease. This activity examines issues relevant to the care of an HIV-infected patient who has major depression and other complicating mental health problems.

 

Intended Audience

This enduring material is designed for physicians who are actively treating or will be treating patients with HIV infection.

This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.

 

CME Information

Accreditation

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The IAS–USA designates this enduring material for a maximum of 1.50AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from September 23, 2017, to September 23, 2018. Physicians (MDs, DOs, and international equivalents) who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Other health care practitioners will receive a Certificate of Participation.

Nursing Continuing Education Contact Hours

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.5 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Pharmacy Continuing Education Contact Hours

Accreditation Council for Pharmacy Education logoEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit

UAN  # 0761-9999-16-274-H01-P

 

Faculty

Authors

Francine Cournos, MD
Dr Cournos is a Professor of Clinical Psychiatry (in Epidemiology) at Mailman School of Public Health, Columbia University, in New York, New York, and a Principal Investigator of the Northeast/Caribbean AIDS Education and Training Center. Dr Cournos has worked at the interface of HIV infection and mental illness since 1983 in a broad range of roles including policy development, administration, clinical care, research, training, and guideline development in national and international settings.

Milton L. Wainberg, MD
Dr Wainberg is a Professor of Clinical Psychiatry at Columbia College for Physicians and Surgeons in New York, New York, the Director of the Columbia University Global Mental Health Research Fellowship, and the Principal Investigator of PRIDES sSA (Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence-Based Practices in sub-Saharan Africa). Dr Wainberg has worked at the interface of HIV infection and mental illness and substance use since 1992 in many roles including clinical care and clinical training, research and research training, national and international guideline and policy development, and administration.

Editor

Joseph F. Murray, MD
Dr Murray is an Associate Professor of Clinical Psychiatry at Weill Cornell Medical College in New York, New York. Dr Murray was a psychiatrist at New York Presbyterian Hospital’s Center for Special Studies, a multidisciplinary HIV/AIDS clinic, for 11 years and remains on the psychiatry consultation staff at New York Presbyterian Hospital in New York, New York.

 

Disclosure of Financial Interests

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

Faculty

Dr Cournos and Dr Wainberg have no relevant financial affiliations to disclose. (Updated 09/23/17)

Editor

Dr Murray has no relevant financial affiliations to disclose. (Updated 09/25/17)

 

Grant Support

2017 Grant Support

For our HIV efffort:

  • PLATINUM SUPPORTER
    ViiV Healthcare
  • GOLD SUPPORTER
    Gilead Sciences, Inc
  • SILVER SUPPORTERS
    Bristol-Myers Squibb
    Janssen Therapeutics
  • BRONZE SUPPORTER
    Merck

For our viral hepatitis effort:

  • GOLD SUPPORTERS
    Gilead Sciences, Inc
    Merck
  • SILVER SUPPORTER
    AbbVie

 

Cases on the Web Editorial Board

Members of the COW Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program. Listed below are the COW Editorial Board members and their financial interests with commercial companies within the past 12 months from the date of disclosure. Click here to view the COW Editorial Board.

 

Drug and Product Disclaimer

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this COW activity.

The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.

 

Contact Information

If you have any questions about this COW activity, please contact the IAS–USA:

IAS–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: info“at”iasusa.org